Biotech Values

[genisi]

If GS-7977/Riba lacks acceptable potency in GT1/GT1A do you think GILD would partner with BMY or Tibotec as opposed to focusing only on an in-house combo?

I think they'll do both i.e go ahead with the best partner to get a combo (that has a reasonable chance of beating ABT's 4-drug combo, at least on the adverse events side) to the market and keep developing a future next gen in-house one.